Cell Gene Medicine

Cell Gene Medicine (CGM) is a clinical-stage biotechnology company based in South Korea that specializes in the development of advanced cell and gene therapies. The company utilizes a proprietary platform that combines adeno-associated virus (AAV) vector technology with mesenchymal stem cells (MSCs) to treat chronic degenerative and inflammatory diseases. Its lead candidate, CGM-101, is a gene-modified cell therapy currently in Phase 1/2 clinical trials for the treatment of osteoarthritis, designed to provide long-term therapeutic protein expression within the joint. CGM's pipeline also includes programs for liver cirrhosis and spinal cord injury, leveraging high-efficiency viral delivery systems to address significant unmet medical needs. The company was founded as a spin-off from Hanyang University and continues to focus on the convergence of viral vector engineering and regenerative medicine.